Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Related Articles
Program Directors’ Selection Criteria for Urology Residency Match in a United States Medical Licensing Examination Step 1 Pass/Fail Era | Urology Practice
Introduction:Program directors of urology residencies have historically weighted the United States Medical Licensing Examination Step 1 heavily to select interview candidates. In January 2022, the…
OnabotA for OAB: Enhancing comfort and ensuring adherence
Karyn S. Eliber, MD,’s follow-up protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA
Urology Care Foundation – Men’s Health Month – Social Media Toolkit
Men’s Health Month – Social Media Toolkit
Even “Low-Risk” Proteinuria Portends Adverse Kidney Outcomes in IgA Nephropathy
Patients with IgA nephropathy may experience faster disease progression than previously appreciated.
MANAGEMENT OF ERECTILE DYSFUNCTION – Uroweb
The EAU Sexual and Reproductive Health Guidelines aim to provide a overview of the aspects relating to sexual and reproductive health in adult males.
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
The approval is supported by findings from the phase 3 ENVISION trial.
Strategies to bridge gender disparities in AAS and citations in the oncology literature
One key approach is to increase the representation of women on editorial boards of journals and as reviewers.
Holtgrewe Legislative Fellowship Program – American Urological Association
The program is open to all AUA residents in their research year, fellows, and first year post-graduates. Applicants will demonstrate a strong interest or aptitude…
Consortium Aims To Advance Science Around Male Infertility
A multi-institutional consortium called MOBY.US (Male Organ Biology Yielding United Science) is combining forces and sharing data to advance the robustness of research into male…
Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.